Abbott Medical Optics, Inc. v Alcon Laboratories, Inc

Link copied
Case Copied 52 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Abbott Medical Optics, Inc. v Alcon Laboratories, Inc. [2011] APO 79

Opponent:Abbott Medical Optics, Inc.

Delegate:Dr B. Akhurst

Decision Date:  26 September 2011

Hearing Date:  7 October 2010 and 11 May 2011 in Canberra, then completed by further written submissions filed on 30 August 2011 and 6 September 2011.

Catchwords:  PATENTS - section 59 - opposition to the grant of a patent - claims construction - novelty - claims lack novelty over prior published information - claims lack novelty in light of the prior use of a product in accordance with the manufacturer’s instructions - strict proof requirement - inventive step - claims lack inventive step over published prior art - clarity in view of typographical error - opposition succeeds on the grounds of novelty, inventive step and clarity.

Representation:  Patent applicant:  Glenn McGowan SC, instructed by patent attorney Dr Simon Weisman of FB Rice & Co., Sydney.

Opponent:Dr Linda Govenlock (Senior Associate) and Dr Trevor Davies (Partner), patent attorneys of Allens Arthur Robinson, Sydney.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2004201867

Title:  Process for cleaning and disinfecting contact lenses

Patent Applicant:  Alcon Laboratories, Inc.

Date of Decision:  26 September 2011

DECISION

The opposition succeeds.  The subject matter of claims 1-5, 9 and 11-17 is not novel.  Claims 1 and 2 lack an inventive step.  Claim 20 is not clear.  The amendments to the claims filed under section 104 on 11 May 2011 are similarly deficient.  Alcon is allowed 2 months to file amendments to overcome the deficiencies in the claims.  Costs are awarded against Alcon Laboratories, Inc.

REASONS FOR DECISION

Background

  1. Patent application 2004201867 was filed by Alcon Laboratories, Inc (‘Alcon’) on 30 April 2004, as one of a series of divisional applications derived from application 76730/94 and claiming priority from US basic document 08/113,142 filed on 27 August 1993.  The related applications are listed below, with subsequent applications each divided from the one above.

    Application No            Filing date  Status

    76730/94  24 August 1994  Lapsed

    71874/98  11 June 1998  Sealed as patent No. 733386

    54175/01  2 July 2001  Lapsed

    2004201867               30 April 2004  Accepted

    2011202183               11 May 2011  Filed

  1. Application 2004201867 was advertised accepted on 3 January 2008.  A notice of opposition to grant of a patent was filed on 2 April 2008 by Advanced Medical Optics, Inc., followed by a statement of grounds and particulars on 2 July 2008.  On 16 September 2009, the notice of opposition was amended under regulation 5.3B to change the name of the opponent to Abbott Medical Optics, Inc. (‘Abbott’).

  1. Abbott filed no evidence in support despite gaining an extension of 3 months to 2 January 2009 in which to do so.

  1. Evidence in answer was served on 2 November 2009, consisting of statutory declarations by

    ·     Dr Masood Chowhan dated 26 October 2009 (Chowhan#1), and

    ·     Dr Howard Ketelson dated 26 October 2009.

  1. Evidence in reply was completed on 30 April 2010, consisting of statutory declarations by

    ·     Dr Linda Jane Govenlock dated 1 February 2010…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Abbott Medical Optics, Inc. v Alcon Laboratories, Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2011] APO 79
Decision Date

CaseChat Overview and Summary

Abbott Medical Optics, Inc. opposed the grant of a patent to Alcon Laboratories, Inc. The opposition was based on several grounds, including lack of novelty, inventive step, and clarity. The decision was rendered on 26 September 2011. The court found that the subject matter of claims 1-5, 9, and 11-17 was not novel, as it was anticipated by prior use and publication of information. Additionally, claims 1 and 2 lacked an inventive step over the prior art, and claim 20 was unclear due to a typographical error. The court allowed Alcon two months to amend the claims to overcome the deficiencies. Costs were awarded against Alcon Laboratories, Inc.

The court first constricted the claims, focusing on claims 1 and 2, which defined the scope of the patent. The court found that claims 1 and 2 lacked novelty, as they were anticipated by prior publications and prior use of Opti-Free® Rinsing, Disinfecting and Storage Solution. The court also found that claims 1 and 2 lacked an inventive step over the prior art. The court found that claim 20 was unclear due to a typographical error in the concentration of sodium citrate.

The court concluded that Abbott had succeeded in its opposition, and the patent grant was not valid. The court allowed Alcon two months to propose amendments to the claims to overcome the deficiencies identified. Costs were awarded against Alcon Laboratories, Inc., as the opposition proceedings had been prolonged by the conduct of both parties.

Background

Background to the litigation

Alcon Laboratories, Inc. filed a patent application for a "Process for cleaning and disinfecting contact lenses." The invention involved a method of cleaning and disinfecting contact lenses using a single solution containing polycarboxylates or corresponding acids, without the need for a separate disinfectant. The application was opposed by Abbott Medical Optics, Inc. who claimed that the invention lacked novelty, inventive step, and was unclear. The opposition was based on prior publications and prior use of contact lens care solutions. The opposition included arguments about the construction of the patent claims, the sufficiency of the evidence provided, and the interpretation of various technical terms.

The patent application 2004201867 was filed by Alcon Laboratories, Inc. on 30 April 2004. The application was one of a series of divisional applications derived from an earlier application. Abbott filed a notice of opposition on 2 April 2008, followed by a statement of grounds and particulars on 2 July 2008. The opposition hearing took place in two parts: on 7 October 2010 and 11 May 2011 in Canberra. Further written submissions were filed by both parties after the second hearing. The hearing was concluded by additional written submissions on 30 August 2011 and 6 September 2011. The decision was issued on 26 September 2011.

Decision

Reasons for decision

Issues
1. Whether the subject matter of claims 1-5, 9 and 11-17 of the patent application is novel over the prior art.
2. Whether the subject matter of claims 1 and 2 of the patent application lacks an inventive step over the prior art.
3. Whether the subject matter of claim 20 of the patent application is clear.
4. Whether the patent claims are fairly based on the matter described in the specification.

Held
1. The opposition to the grant of the patent was successful.
2. The subject matter of claims 1-5, 9 and 11-17 of the patent application is not novel.
3. The subject matter of claims 1 and 2 of the patent application lacks an inventive step.
4. Claim 20 of the patent application is not clear.
5. The amendments to the claims filed under section 104 on 11 May 2011 are similarly deficient.
6. The patent applicant, Alcon Laboratories, Inc., is allowed 2 months to file amendments to overcome the deficiencies in the claims.
7. Costs are awarded against Alcon Laboratories, Inc.

Ratio Decidendi

Legal Principle Established

In this case, the court was tasked with determining whether the patent application met the criteria for novelty, inventive step, clarity, and fair basis under Australian patent law. The opposition was brought by Abbott Medical Optics, Inc. against Alcon Laboratories, Inc., the patent applicant. The court examined the patent claims in light of prior art and the content of the specification.

The court first considered the issue of novelty, determining that claims 1-5, 9, and 11-17 were anticipated by prior art, including the Opti-Free® RDS package insert, which contained instructions for using the Opti-Free® Rinsing, Disinfecting and Storage Solution. The package insert provided a method that inevitably led to the claimed invention, involving the use of a single solution to clean and disinfect contact lenses.

Regarding the inventive step, the court found that claims 1 and 2 lacked an inventive step in light of the prior art documents US'195 and US'239. These documents disclosed methods for cleaning contact lenses using solutions that included polycarboxylic acids, which was known prior to the priority date. However, claims 3-21 were found to involve an inventive step as they were not suggested by the prior art.

The court also examined the clarity of the claims. While claims 1-19 and 21 were found to be clear, claim 20 was deemed unclear due to a typographical error that resulted in a concentration of citric acid that was less than the effective amount required.

Finally, the court assessed whether the claims were fairly based on the matter described in the specification. The court concluded that the claims were fairly based as the specification provided a real and reasonably clear disclosure of the claimed invention.

In conclusion, the opposition was successful on the grounds of novelty, inventive step, and clarity. Alcon was granted two months to file amended claims to overcome the deficiencies identified by the court. Costs were awarded against Alcon Laboratories, Inc.